Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
FDA Approves MSD's Keytruda Combo for Platinum-Resistant Ovarian Cancer
FDA approves MSD’s Keytruda combo for platinum-resistant ovarian cancer. KEYNOTE-B96 data shows improved survival in PD-L1 positive patients.
Madrigal Expands MASH Pipeline with $4.4bn siRNA Deal with Suzhou Ribo
Madrigal signs $4.4bn deal with Suzhou Ribo for siRNA MASH therapies. Partnership targets liver disease pathology and Rezdiffra combination potential.
FDA-Approved Seizure Drug Levetiracetam May Prevent Alzheimer's Plaques
Northwestern study finds levetiracetam blocks toxic amyloid-beta 42 in synaptic vesicles, offering a new prevention strategy for Alzheimer's disease.
Devonian Reports Positive Preclinical Data for Thykamine in Lung Fibrosis
Preclinical Study: CAR-T Cell Therapy Clears Alzheimer’s Amyloid Plaques
PNAS study reveals engineered CAR-T cells reduce amyloid plaques in Alzheimer’s models. A potential shift in immunotherapy for neurodegenerative disease.
FDA Issues Refusal-to-File Letter for Moderna’s Seasonal Flu mRNA Vaccine
FDA issues refusal-to-file for Moderna's mRNA-1010 flu vaccine, citing inadequate comparator. Moderna disputes the decision regarding standard of care.
Eli Lilly Buys Orna Therapeutics for $2.4bn: A Bet on In Vivo Cell Therapy
Eli Lilly acquires Orna Therapeutics in a $2.4bn deal, gaining access to circular RNA and in vivo CAR-T therapies for B-cell-driven autoimmune diseases.
Novartis Begins Construction on New Global Research Facility in San Diego
Novartis starts building a $23bn research hub in San Diego. The 466,000ft² facility targets oncology, neuroscience, and gene therapies, opening in 2029.
Enanta to Present EDP-978 Preclinical Data at 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals to present EDP-978 KIT inhibitor data for Type 2 immune diseases at the 2026 AAAAI Meeting. Learn about potent mast cell treatments.
NanoViricides Seeks FDA Orphan Drug Status for NV-387 Measles Treatment
NanoViricides files for US FDA Orphan Drug Designation for NV-387. A breakthrough broad-spectrum antiviral targeting the global measles resurgence.
Senolytics Clear 70% of 'Zombie' Cells: Breakthrough Preclinical Study Results
Cedars-Sinai study shows senolytics eliminate 70% of 'zombie' cells. Learn how new senosensitizers target resistant cells to combat aging diseases and cancer.
U.S. FDA Grants Mexiletine Orphan Drug Designation for Myotonic Disorders
Lupin announced U.S. FDA granted Orphan Drug Designation to mexiletine hydrochloride for the treatment of myotonic disorders.
4
5
6
7
8
9
10
11
12
